UCSF Benioff Children's Hospital Antimicrobial Susceptibility: Pediatric Inpatient/ED, Incidence-Weighted Gram-Negative Coverage By Drug

PrintPrintPDFPDF

The table below lists the % of Gram-negative organisms that tested susceptible to each listed drug or combination in 2016-2018.  With changes in report methods, this report will now be updated every 3 years. The values incorporate the frequency with which the various organisms were isolated as well as their sensitivity to the drug; more commonly isolated organisms contribute more to the overall susceptibility results.  Results are based on standard methodology.

Population Number of Isolates Ceftriaxone Ceftazidime Cefepime Pip/tazo Meropenem
All inpatient/ED isolates 970 77% (89%)* 91% 97% (97%)# 94% 99%
ICN  126 81% (89%)*, ** 91% 97% (98%)# 94% 98%
PICU & CICU  162 56% (81%)* 83% 93% (93%)# 90% 98%
non-ICU  682 81% (91%)* 92% 98% (98%)# 95% 99%

* Value in parenthesis is susceptibility if Pseudomonas and Acinetobacter are excluded

** Gentamicin susceptibility among ICN Gram-negative isolates is 84% (93% if Pseudomonas and Acinetobacter are excluded)

# Value in parentheses represents the percentage of isolates both fully susceptible and susceptible-dose depedent to cefepime. Susceptible-dose depedent isolates are Enterobacteriaceae with MIC 4 to 8 micrograms/mL for which a high dose of cefepime is anticipated to be active. Consult Pediatric ASP or ID for guidance on treating isolates reported as susceptible-dose depedent.

Gram Negative Combinations by Location

The table below details the percent susceptibility of inpatient Gram-negative isolates to single agents and to the combination of antimicrobials indicated (number to the right of the arrow). Data are from 2016-2018.

MER = meropenem; TOB = tobramycin; PIPTAZ = piperacillin/tazobactam; CFPM = cefepime; CIP = ciprofloxacin

Population Number of Isolates

PIPTAZ -->

PIPTAZ + CIP

PIPTAZ -->

PIPTAZ + TOB

CFPM# --> 

CFPM + CIP

CFPM# --> 

CFPM + TOB

MER --> 

MER + CIP

MER --> 

MER + TOB

All inpatient/ED isolates 970 94% --> 99% 94% --> 99% 97% --> 99% 97% --> 99% 99% --> 99% 99% --> 100%
ICN 126 N/A 94% --> 99% N/A 98% --> 99% N/A 98% --> 100%
PICU & CICU 162 90% --> 98% 90% --> 100% 93% --> 96% 93% --> 97% 98% --> 99% 98% --> 100%
non-ICU 682 95% --> 99% 95% --> 98% 98% --> 99% 98% --> 99% 99% --> 100% 99% --> 100%

 

# Numbers for cefepime combination threapy analysis are based on the percentage of isolates both fully susceptible and susceptible-dose depedent to cefepime.